The development of therapeutic recombinant antibodies involves accurate characterization of immunoglobulin variable light (VL) and heavy (VH) chains. However, it has been reported that the use of subgroup or isotypespecific primers for the amplification of monoclonal antibody (mAb) variable domains introduces heterogeneities within the variable domains, or amplifies aberrant productive Ig domains. To address these issues, we have combined the rapid amplification of cDNA ends PCR (RACE-PCR) for the full-length VL and VH amplification, with peptide mass fingerprinting of the corresponding Ig chain. Using this strategy, we amplified full-length cDNA chains of SAF34 and SAF32, two potential therapeutic mAbs against neurodegenerative diseases directed to the prion protein (PrP). We report an unambiguous correlation between hybridoma cDNA sequences and protein fingerprints of the variable domains of each mAb, indicating the discrimination between mutated, pseudogenes and functional Ig genes. As a proof of principle for this dual strategy of full-length PCR amplification of variable domains and their characterization by MALDI-TOF, we show that the corresponding scFvs recognize the native PrP and retain full capacity to bind to human PrP, as does the parental mAb. This finding addresses the need for reliable light and heavy chain characterization, a key factor for humanization of mouse antibodies and for its use in passive immunotherapy applications.
Introduction
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are neurodegenerative disorders that occur in animals as well as in humans; they are caused by the conversion of the host cellular prion protein (PrP C ) into a pathological conformer termed scrapie prion protein (PrP Sc ), which folds abnormally and polymerizes into fibrillar structures called scrapie-associated fibrils (SAFs) in diseased cells (Merz et al., 1981; Prusiner, 1982; Prusiner et al., 1982) . As of June 2008, more than 190 000 cases of BSE and a total of 208 individual cases of variant Creutzfeldt-Jakob disease (vCJD) had been reported worldwide, with more than 90% of bovine spongiform encephalopathy (BSE) and vCJD, the human form of 'mad cow' disease, confirmed in the UK, and each year about 6000 new patients develop classic Creutzfeldt-Jakob disease according to the Center for Disease Control and Prevention (CDC). Despite tremendous research efforts, and even though the number of reported cases has declined, an effective therapy against prion diseases has not yet come to market.
Since published reports of anti-PrP monoclonal antibodies antagonizing prion propagation in vitro and in vivo (Heppner et al., 2001; Peretz et al., 2001; Feraudet et al., 2005) , immunotherapy has emerged as a promising treatment for TSEs. In our laboratory, we have produced and tested 145 mouse mAbs against PrP for their capacity to decrease the constitutively expressed abnormal isoform of prion protein (PrP Sc ). In particular, the mAbs SAF34 and SAF32 hold the greatest promise because of their ability to lower PrP Sc levels in a cell-based assay (Perrier et al., 2004; Feraudet et al., 2005) . Moreover, very recently, monoclonal Abs directed against the normal protein prion (PrP C ) have been reported to constitute a new potential therapeutic application for Alzheimer disease (AD), as described by scientists at Yale University (Lauren et al., 2009 ). Their work demonstrates (i) that the cellular prion protein (PrP C ) of neurons is an amyloid-beta-oligomer receptor responsible for impairment of synaptic plasticity in Alzheimer's disease, and (ii) that anti-PrP C antibodies prevent amyloid-beta-oligomer from binding to PrP C and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. This incurable disease affects more than 27 million people worldwide (Brookmeyer et al., 2007) . The economic burden of Alzheimer's disease is massive; in the US alone, the estimated direct and indirect annual cost of patient care is at least $100 billion. Current FDA-approved drugs for Alzheimer's disease do not prevent or reverse the disease, and provide only modest symptomatic benefits (Rafii and Aisen, 2009) . In this context, immunotherapy with mAbs directed against PrP C could be a promising approach to stabilize or to treat AD. However, despite their potent clinical applications, the use of these Abs in humans, as for most mAbs raised in mice, is difficult (Carter, 2001) ; mouse Abs can elicit a human anti-mouse antibody immune response. To reduce their immunogenicity, mouse mAbs have to be chimerized, or humanized, before they can be used therapeutically; this involves the drafting of only mouse complementarity determining regions (CDRs) in between human frameworks (FRs), while the chimeric mAb is designed to contain mouse variable domains and human constant regions (Kettleborough et al., 1991; Mountain and Adair, 1992; Liu et al., 2008) . To enable the construction and expression of such corresponding recombinant antibodies that preserve the functional features of the original mouse mAb for use in patients, we need an accurate characterization of the cDNA that encodes the variable light (VL) and heavy (VH) domains of the potential therapeutic mAbs (Krebber et al., 1997) . However, despite considerable recent technical progress, cDNA cloning of Ig VL and VH domains remains a challenging procedure. A number of studies have shown that up to three aberrant chains, from pseudogenes, allelic excluded genes, out-of-frame sequences or from the myeloma fusion partner or the fused B-cell, can be amplified, in addition to the functional chains for any mouse mAb hybridoma (Cabilly and Riggs, 1985; Carroll et al., 1988; Ostermeier and Michel, 1996; Vidarsson et al., 2001) . Thus, the design of Ig-specific primers is essential for successful reverse transcription (RT) cloning. Attempts have been made to optimize those primer sets (Krebber et al., 1997; Wang et al., 2000; Seijen et al., 2001; Essono et al., 2003; Zhang et al., 2006) . However, because of degeneration and mis-match annealing, the use of subgroup-specific primers introduces heterogeneity within the framework nucleotide sequences, FR1 and FR4 Taylor et al., 2007) : a single amino acid exchange within the CDRs or FRs has been reported to influence the folding efficiency of the corresponding recombinant antibody (Knappik and Pluckthun, 1995; de Haard et al., 1998) , thus compromising recombinant antibody properties by introducing changes within the initial amino acid residues of FR1 and FR4 (Chothia et al., 1989; Honegger and Pluckthun, 2001) .
We have developed a complete cloning strategy to generate and validate cDNA that encodes the immunoglobulin variable domains. In contrast to classic RT -PCR approaches, the peptide mass-assisted antibody cloning strategy (PAACS) combines RACE-PCR for the amplification of full-length VL and VH domains without the artifacts often encountered with the use of subgroup-specific primers, mass spectrometry peptide mapping of the corresponding Ig VL and VH domains that yield a sensitive method for validation of the cDNA cloning and a final functional assay of the corresponding recombinant antibody (Fig. 1) .
This strategy provides direct insight into the accuracy of cloning the Ig variable domains by combining a RACE-PCR full-length of VL and VH domains and a MALDI-TOF MS characterization, which ensures that the cDNAs cloned correspond to the Ig protein expressed by the hybridoma of interest. The results of this study have implications for the optimization of mAb light and heavy chain characterization, a key element for developing the next generation of therapeutic recombinant antibodies by different approaches:
antibody libraries, phage display, domain antibodies (dAbs) and antibody humanization to name a few (Dimitrov and Marks, 2009 ).
Materials and methods

Total RNA isolation from mouse hybridomas
Hybridomas cultured in a selective medium (RPMI 1640 supplemented with 15% heat-inactivated fetal calf serum, 2 mM L-glutamine, 2 mM sodium pyruvate, 5 Â 10 22 mM hypoxanthine, and 10 22 mM azaserine) were used for isolation of total RNA. The RNAs were extracted from 1-5 Â 10 6 hybridoma cells and processed with the Genelute mammalian total RNA kit (Sigma-Aldrich Corporation, St Louis, MO, USA). Antibody isotypes were determined by the Ouchterlony technique (Ouchterlony et al., 1952) . Integrity, purity and concentration of the total RNA were checked on an Agilent 2100 Bioanalyzer system (Agilent Technologies, Santa Clara, CA, USA).
RACE-PCR
Full-length cDNA sequences of light and heavy chains were assessed by RACE-PCR. The upstream VL and VH sequences were extended by 5 0 -RACE-PCR using the GeneRacer Kit (Invitrogen, Carlsbad, CA, USA). Total RNA (5 mg) was reverse-transcribed using the following sets of gene-specific primers (GSPs): K-GSP CACTCATTCCTGT TGAAGCTCTTGACGATGG for kappa light chain amplification, IgG2A-GSP ACCCGGAGTCCGGGAGAGCTCTT AGTCGTGTGG for SAF32 heavy chain amplification and IgG2b-GSP TTTACCCGGAGACCGGGAGATGGTCTTCT TCAGG for SAF34 heavy chain amplification. All GSPs are located at the 3 0 terminus constant region of each mouse Ig and were used in combination with Invitrogen's adaptor primers (GeneRacer 5 0 primer and GeneRacer 5 0 nested primer). First, 2 ml of RT template was amplified, using 10 mM reverse GSP and 10 mM GeneRacer 5 0 primer, mixed with 2.5 or 4.5 mM MgCl 2 in the reaction buffer, 0.5 mM of dNTP and 2.5 units of AccuTaq DNA polymerase (Sigma-Aldrich Corporation, St. Louis, MO, USA). RACE-PCR was carried out with an initial denaturation at 948C followed by 25 cycles as follows: 948C for 30 s, annealing at 688C for 30 s and extension at 688C for 2 min; a final extension was done at 688C for 7 min. Next, 1 ml of the resultant RACE-PCR product was subjected to nested PCR, initially using the GeneRacer 5' Nested GeneRacer Kit (Invitrogen, Carlsbad, CA, USA), then using the reverse nested primers kappa-GSP GTGAGTGGCCTCACAGGTA TAGC and IgG2a-GSP GGCTCAGGGAAATAACCCTTG ACCAGGCATCC and IgG2b-GSP GGCTC AGGGAAG TACCCCTTGACCAGGCACCC for each type of chain. This RACE-PCR was carried out with an initial denaturation at 948C for 3 min followed by 25 cycles each of: denaturation at 948C for 30 s followed by annealing at 608C for 30 s, extension at 688C for 30 s and a final extension at 688C for 7 min. Following each PCR run, 5 ml of the yield was analyzed on 2% agarose gel. The expected bands were gelpurified and 1 ml of the resulting product was cloned into the sequencing pCR4-TOPO vector (Invitrogen Corporation, Carlsbad, CA, USA). Sequence analysis and germline gene identification were performed using the IMGT-V-Quest software (IMGT, the international ImMunoGeneTics database http://imgt.cines.fr:8104); sequence alignment was done using (http://prodes.toulouse.inra.fr /multalin/multalin.html) Multalin software.
Specific V-D-J amplification and scFv assembly
After characterizing each sequence, specific primers were designed to amplify the entire variable domains VL and VH (V-J and V-D-J regions) for light and heavy chains, respectively. VH and VL products were assembled by overlap extension PCR (SOE-PCR) (Horton et al., 1989 ) with a 20-amino-acid linker [Gly4Ser]4 (Krebber et al., 1997) . Each product was cloned into the SPI 3.0 vector, a prokaryote expression plasmid derived in our laboratory from the pET26b vector (Novagen, Madison, WI, USA); we introduced an additional N-terminal HA-Tag and a C-terminal His-Tag for detection and purification purposes (Boquet et al., 2000) . Two different SfiI enzyme sites were introduced for scFv directional subcloning. The construct SPI.3.0-HAscFv-His was electroporated into Escherichia coli BL21 (DE3). Clones were selected on kanamycin LB plates, and screened by PCR using insert-specific primers.
Single chain-Fv expression SAF32 and SAF34 scFv were produced using the prokaryote periplasmic expression vector SPI 3.0 (Boquet et al., 2000) and the E.coli BL21(DE3) expression strain (Novagen, Madison, WI, USA). Briefly, expression of recombinant scFvs SAF32 and SAF34 was carried out in a 2 ml deep-well plate (Eppendorf AG, Germany) as follows: 30 ml of overnight culture was used to inoculate 1.5 ml of kanamycin-LB medium, incubated for 2.5 h at 378C, shaken (230 rpm) until it reached an optical density of 0.125 at 620 nm and was then induced with 1 mM IPTG followed by an additional 5-h incubation at 308C (230 rpm). Cells were then pelleted, suspended in 300 ml of PBS (0.1 M phosphate, pH 7.4, 0.15 M NaCl, 0.01% sodium azide) and kept on ice for 30 min and shaken at 100 cycles/min. Supernatant containing the soluble periplasmic extract was collected and stored at 2208C.
Detection of full-length and active scFvs by ELISA
Periplasm extracts containing the HA-scFv-His vector were screened and their properties were analyzed by means of two different immunometric assays as previously described (Boquet et al., 2000) . Briefly, in order to detect full-length scFv or the functional scFvs, plates coated with mAb12CA5 (anti-tag Myc) were incubated with 50 ml of periplasmic extract and with 50 ml of enzyme tracer that corresponded either to an anti-Tag-His mAb (PolyHis-24) coupled with acetylcholinesterase (AChE, EC 3.1.1.7) for the double Tag detection, or to an epitope peptide named Pri-0 (GGWGQPHGGGWGQG) that corresponds to the flexible octa-repeats region on PrP protein, and that is conjugated with AChE (2 Ellman units/ml) for functional detection. Plates were washed three times with 10 mM phosphate buffer, at pH 7.4, containing 0.05% Tween 20, and solid phase-bound AChE activity was measured according to the modified Ellman method (Pradelles et al., 1985) .
Peptide mass fingerprinting analysis
Monoclonal antibodies were resolved by one-dimensional SDS-PAGE and Coomassie blue staining using a PhastSystem (GE Healthcare, Piscataway, NJ, USA). Proteins were in-gel digested with 40 ng/ml porcine trypsin (Promega) at 588C for 30 min, 1 h or 15 h and the peptides were crystallized with a-cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich Corporation, St Louis, MO, USA) using the dried drop method on a MALDI-TOF MS (matrix-assisted laser desorption ionization time of flight mass spectrometry) plate. All steps were completed according to the EMBL online protocol (www.narrador.embl-heidelberg.de). Mass spectrometry analysis was carried out with MALDI-TOF MS , and spectra were generated with a Voyager DE-RP instrument (Applied Biosystems Inc, Foster City, CA, USA) in a positive ion mode. Theoretical digestion of proteins deduced from cDNA was performed by the MS-Digest software from the Protein Prospector package (http://prospector.ucsf.edu/). The parameters of MASCOT Peptide Mass Fingerprint and Protein Prospector MS-Fit used to identify the proteins in the swissprot databank were: (i) search limited to mus musculus taxonomy category, (ii) trypsin digestion with two missed cleavages authorized, (iii) possible modification: carbamidomethyl, (iv) non-charged, monoisotopic data with a mass tolerance of 0.1 Da.
Results
RACE-PCR and sequence analysis
To assess the full-length Ig VL and VH domains without the use of 'universal' degenerate primers, we chose to amplify the cDNA of Ig-chains, by RACE-PCR. The SAF34 PCR products obtained are shown in Fig. 2A . Two bands were identified for the light chain (lane 1 and 2 VL), one spanning 800 bp as expected, the other corresponding to a non-specific amplification at $350 bp. One specific product was observed for the heavy chain at the expected size of 1500 bp (lane 1 and 2 VH). Under the conditions used, no effect of MgCl 2 concentration on the PCR efficiency [compare line 1 (2.5 mM) with line 2 (4.5 mM), Fig. 2A ], and no signal was detected in lane C (negative control), indicating the absence of PCR contamination. Results for mAb SAF32 were similar (data not shown). The expected VL and VH bands were gel purified, subcloned into the pCR4-TOPO vector used to transform BL21 (DE3) E. coli.
Detailed analysis of rearranged Ig nucleotide sequences, with reference to the IMGT/V-QUEST mouse reference directory sets of sequences, showed that the amplified sequences corresponded to full-length immunoglobulin sequences (VJC or V-D-J-C) for the light and heavy chains, respectively (EMBL accession no. FM163488, FM163489, FM163490 and FM163491). In addition, the alignment results show that the mobilized light chains (Fig. 2, Part B1 ) share 98.97 and 98.63% similarity to the IGKV1-135*01 allele for the V gene, and 100.0% similarity to the same IGKJ1*01 J gene (alignment not shown) for SAF32 and SAF34, respectively.
A corresponding search for IgH-SAF32 and IgH-SAF34 against the IMGT/V-QUEST reference directory for mouse IGH genes (Brochet et al., 2008) revealed matches with the subgroup IGHV9-3*01 allele (Fig. 2 Part B2) for the V gene (98.96 and 96.88% identity, respectively). Matches with the IGHJ4*01 allele for the J gene were 92.45% for both heavy chains, and with IGHD2-5*01 for the D gene, 81.82 and 77.78% identity, respectively. Nucleotide similarity between the two VL and two VH domains of SAF32 and SAF34 was 96.6 and 91.9%, respectively, suggesting that the same V-J and V-D-J rearrangements were used to identify the same epitope, but that they differed by somatic mutations.
The corresponding translated amino acid sequences showed that all four sequences were in frame, and contained the key structural amino acids cysteine 23, tryptophan 41 and leucine 89, conserved according to IMGT numbering (Lefranc et al., 2003) . Moreover, the two VL and VH have the same CDR-IMGT length [11.3.9] and [8.8.12], respectively.
Amino acid comparison between light chains and the corresponding mouse IMGT representative match showed two amino acid changes: V101 . I (FR3) and T108 . S (CDR3-S) for SAF32 VL, and A19 . V (FR1) and G107 . N (CDR3) for SAF34 VL. For the heavy chains, when compared with the most closely matched mouse IGHV regions, two amino acid changes, V42 . M (FR2) and V64 . M (CDR2), were found from position 1 to 104 for SAF32 VH, and three amino acid changes V5 . A(FR1), E81 . D and N93 . I (FR3), were found for SAF34 VH. At this stage of the analysis, the key question was whether these observed mutations were the result of an affinity maturation process, or of artefactual amino acid changes resulting from an errorprone PCR.
Peptide mass fingerprinting characterization of mAb chains
To confirm that the DNA sequences amplified by RACE-PCR were the functional ones corresponding to the antibodies produced by the hybridoma of interest, all light and heavy mAb chains were characterized by peptide mass fingerprinting using MALDI TOF MS (Kuster and Mann, 1998) . SAF32 and SAF34 mAbs were run on SDS -PAGE. The VH and VL bands were in-gel reduced, carbamidomethylated and trypsin-digested for MALDI-TOF MS analysis. A representative MALDI spectrum of the mAb SAF34 light chain is shown (Fig. 3A) . Numerous monoisotopic masses had high-quality peak intensities and were scattered across the entire spectrum, ranging from 500 to 4100 Da. Results of the fingerprinting search database identified mouse Ig sequences as first hits.
To correlate the cDNA-cloned sequences with the MALDI-TOF peptide masses, a theoretical digestion of mAbs SAF32 and SAF34 amino acid sequences was performed using the MS-Digest software. In other words, the SAF34 VL domain was in silico tryptic peptide digested: sixteen peptides were generated, with a theoretical mass scale covering 500 -3850 Da. Theoretical and observed masses were correlated by visual comparison, showing recovery of all SAF34 VL domain amino acids. The same characterization was applied to the VH domains, with 100% recovery for SAF34 VH domain, and 90% for the corresponding SAF32 VH domain. We also confirmed that mutations observed in the sequences were present at the protein level and were thus not a result of an error-prone PCR, a point illustrated by the peptide mass analysis of the VL domains (Fig. 3) .
Four amino acids were different between the translation of the SAF32 and SAF34 VL domains: underlined (V, V, N and T) in the SAF34 sequence (Fig. 3B) . Corresponding amino acids in SAF32 were A, I, G and S, respectively. We observed that the SAF34 light chain tryptic peptides '1 -24' and '80 -108' were detected at m/z 2575.109 and m/z 3360.8 Da, respectively (Fig. 3A) . The inset in Fig. 3A shows peptides of the SAF32 light chain, revealing a peak at m/z 2547.116 Da; a shift of 228 Da corresponding to a V 
Single chain-Fv construction, expression and functional characterization
To investigate the functional properties of the cloned VL and VH domains, we assembled them by SOE-PCR, using a linker peptide of 20 amino acids (GGGGS) 4 . The scFv were cloned into the periplasmic expression vector SPI 3.0, which adds one HA-tag at the N-terminal extremity and one His-tag at the C-terminal extremity (Fig. 4A) . We detected the fulllength expressed scFv by ELISA (Boquet et al., 2000) , after transformation into BL21(DE3) E.coli. Several individual colonies with insertions of scFv SAF32 and SAF34 were expressed. We tested the 96 periplasmic extracts for their ability to express entire scFv by double tag ELISA, and in parallel with a second ELISA, to estimate their functional activities against the corresponding antigen epitope (Fig. 4B) . Several periplasmic extracts were selected to illustrate scFv expression in the presence of the wellcharacterized periplasmic extract of scFvSP31 directed against the P substance ( positive control). A neuropeptide of 11 amino acids was added to validate the expression protocol (Boquet et al., 2000) : the negative control corresponded to periplasmic extract from the empty vector. For scFv-SAF32 (Fig. 4B) , 10 colonies were positive in the double tag test, 8 clones (B4, F4, H4, B5, H5, C6, A7 and E7) showing a high functional signal (close to OD 0.8 at 414 nm). For the scFv-SAF34 construct (Fig. 4A) , eight clones (A6, B6, C5, D6, D7, D9, F7 and H6) were positive in both the double tag and functional assays. The remaining non-functional clones probably result from an incorrect assembly of peptide linker or artefactual mutagenesis of a codon, induced by an error PCR, which dramatically alters the expression of scFv. Finally, these functional expression assays allowed us to validate the cDNA cloning of the two mAbs and demonstrate efficient scFv expression, i.e. D5 for SAF32 and C5 for SAF34.
Discussion
We have developed the PAACS approach to address the need for accurate cloning of the VL and VH domains of mAbs. Our approach is based on a rigorous comparison between theoretical translated cDNA peptide fingerprints and the observed results from corresponding VL or VH peptide mass fingerprinting analysis, followed by a validation of the corresponding scFv to guarantee that the functional features of the antibody are maintained. To date, more than 20 antibodies have been cloned in our laboratory by the PAACS approach and their properties in terms of protective effect, specificity and affinity were demonstrated to be identical to those observed in the parental mAb.
Several approaches are currently used for immunoglobulin cDNA cloning. These methodologies commonly use subgroup-specific degenerate primers to amplify the variable domains (Krebber et al., 1997; Chardes et al., 1999; Song et al., 2000) . However, degenerate primers frequently introduce out-of-context mutations into FR1 and FR4, and lead to the amplification of unproductive chains (Krebber et al., 1997; Taylor et al., 2007) . Numerous studies on CDR-grafted antibodies, and site-directed mutagenesis within the FR, demonstrate the importance of FR residues and their influence on antigen binding (Riechmann et al., 1988; de Haard et al., 1998) : for example, the presence of Q (cag codon) or E (gag codon) at position 6 governs the folding of heavy chains (de Haard et al., 1998; Honegger and Pluckthun, 2001 ). In addition, given the fact that the FR1 is structurally close to the VH CDR3, and is believed to be involved in the antigen-binding process, the mutation in the FR1 may lead to an amino acid substitution that compromises the antigenantibody binding (Chien et al., 1989; Chothia et al., 1989) .
These reports directed our choice of 5 0 RACE-PCR for the amplification of a specific product for both heavy and light chains from SAF34 mAb ( Fig. 2A) . The 5 0 RACE-PCR yields successful amplification of full-length cDNA free of supplementary heterogeneities introduced by degenerate FR primers (Jovelin et al., 1995; Doenecke et al., 1997) . Alignment of each VL and VH sequence against the matched IMGT mouse candidate germline genes (Giudicelli et al., 2005; Brochet et al., 2008) shows a relatively high homology, with different numbers and kinds of amino acid changes in the CDR as well as in the FR of SAF32 and SAF34 mAbs (Fig. 2B) .
We also show that the SAF32 and SAF34 mAbs use the same V-J and V-D-J rearrangements for their productive VL and VH domains, in which only 4 and 10 amino acid differences, respectively, are apparent. This strongly suggests that these two mAbs, which originate in the same fusion and are directed against the same epitope, might originate from the same cell precursor but diverge during the switch of the constant region, thus determining the isotype of Ig (IgG2a for SAF34, IgG2b for SAF32), with the introduction of mutations in rearranged DNA during the affinity maturation process. Furthermore, the main differences between SAF32 and SAF34 are located within the junctional regions, i.e. in the VH CDR3. This extensive diversity, because of its central location in the binding site, plays a critical role in VH binding to the antigen, and thus could account for the differences of affinity between the two mAbs (Ward et al., 1989; Kabat and Wu, 1991; Xu and Davis, 2000) .
To rule out possible artefactual mutations introduced by the cDNA amplification step, we carried out peptide mass fingerprinting, which consists of a comparison between the experimental peptide mass fingerprint of the VL and VH chains of the parent mAb and the theoretical tryptic digest of the translated cloned cDNA sequence. The consistent peak intensities from peptide to peptide, and the matching of almost all of the mass values obtained against the cloned sequence, allow a sequence coverage of 90-100% for all variable domains, with significant overlapping peptides, for SAF34 VL (Fig. 3C) . In addition, a search of the mouse NCBI database yielded a reliable match that identifies most peptides as components of the repertoire of the mouse Ig variable or constant regions. Nevertheless, a few short (three to four amino acids) tryptic peptides and higher molecular weight peptides could not be observed by the MALDI, due to interference from the matrix and effects of the range (500 -4000 Da) of output mass used.
In contrast to previous cloning approaches, PAACS offers the advantage of unequivocally correlating the MALDI-TOF mass values with the peptide masses derived from the translated, cloned cDNA. These findings are supported by a report on clarifying the N-terminal amino acid residues of Ig variable domains following the use of degenerate primers; the authors successfully used N-terminal sequencing, MALDI-TOF and nanoelectrospray mass spectrometry characterization to demonstrate the correspondence between the N-terminal of the cloned sequences and the mAb protein product (Taylor et al., 2007) . Another study also showed the usefulness of the peptide mass fingerprinting approach for the de novo sequencing of Ig chains (Pham et al., 2006) . These reports are both consistent with the use of peptide mass fingerprinting for efficient validation of cloned Ig variable domains. However, mass spectrometry and peptide mass fingerprinting are not reliable on their own, and nor are they sophisticated enough at this time for the complete characterization of Ig chains. Nevertheless, the PAACS approach combined with a tamden mass spectrometry (MS/MS) (Bandeira et al., 2008) , allowing to access to amino acid sequence of peptides generated by protease digestion, should be even more powerful than the MALDI-TOF used in the present study. Using the RACE-PCR method, we identified only one unproductive rearranged transcript (for SAF32 VL) that did not correlate with the theoretical mass fragments of the corresponding antibody protein (data not shown). It was readily traced as the MOPC21 unproductive transcript derived from the fusion partner NS1 (see IMGT Lexique, http://imgt.cines.fr). In accordance with previous studies, this finding indicates that even the RACE-PCR cannot prevent amplification of additional unproductive transcripts, if they share the same C gene (therefore same isotype) as the functional Ig chain (Siebenkotten et al., 1992; Irsch et al., 1993) .
To demonstrate periplasmic production efficiency of the scFvs, and also the antigen recognition and inhibition activities of the recombinant antibodies, we investigated their functional properties. We used an ELISA that involves detection of the entire form via N-and C-terminal tags followed by binding to the relevant antigen, for both SAF32 and SAF34 scFvs (Essono et al., 2003) . The SAF34 scFv clone C5 was additionally evaluated for its ability to bind to PrP. Characterization of the mAb and scFv-SAF34 with surface plasmon resonance measurements revealed a K D of 7.9 Â 10 8 and 1.4 Â 10 9 M, for scFv-SAf34 and whole mAb, respectively (data not shown). Thus, the SPR experiments performed with the scFv-SAF34 indicated a 65-fold decrease in the affinity, which falls within a range of affinity typical for an scFv and its ligand. In a recent report, we have shown that the SAF34 scFv recognize the native PrP C expressed on the cell surface (Padiolleau-Lefevre et al., 2007) , a prerequisite for a potent inhibition effect and beneficial for prion passive immunotherapy (Feraudet et al., 2005) . In addition, in this article, we have demonstrated that the SAF34 scFv shares the same specificity and affinity as does the whole antibody or Fab fragment (Padiolleau- Lefevre et al., 2007) and has a potent curative effect similar to that of mAb in blocking PrP Sc replication in a prion-infected cell culture (Perrier et al., 2004, Ollivier Milhavet, personal communication) . These results dramatically underscore that if the amino acid sequence of a variable region of native mAb are conserved in a recombinant antibody format by an adapted cloning strategy, then affinity and specificity properties are conserved.
In conclusion, the PAACS approach allowed the cloning and characterization of all hybridomas tested to date. All these hybridomas were also tested for functional Ag binding in a relatively short time. As increasing effort is being invested in the generation of recombinant antibody fragments, PAACS provides an efficient, sensitive and reproducible approach, which can be applied to any antibody species. Our findings also document that peptide mass fingerprinting analysis may be fully complementary to mAb cloning strategies. These results promise further refinement of sequence conservation between the cloned cDNA and the parental Ab peptide mass fingerprinting pattern, a process that could facilitate the generation and expression of accurately characterized recombinant therapeutic antibodies.
